Literature DB >> 12654623

Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men.

Michael Schoppet, Juergen R Schaefer, Lorenz C Hofbauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12654623     DOI： 10.1161/01.cir.0000060815.25798.02

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  22 in total

1.  Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women.

Authors:  R A Mangiafico; C Alagona; P Pennisi; N Parisi; M Mangiafico; F Purrello; C E Fiore
Journal:  Osteoporos Int       Date:  2007-08-04       Impact factor: 4.507

Review 2.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

Authors:  Linda Demer; Yin Tintut
Journal:  Circ Res       Date:  2011-06-10       Impact factor: 17.367

3.  Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality.

Authors:  Wolfgang Lieb; Philimon Gona; Martin G Larson; Joseph M Massaro; Izabella Lipinska; John F Keaney; Jian Rong; Diane Corey; Udo Hoffmann; Caroline S Fox; Ramachandran S Vasan; Emelia J Benjamin; Christopher J O'Donnell; Sekar Kathiresan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

4.  Adverse effects of hyperlipidemia on bone regeneration and strength.

Authors:  Flavia Pirih; Jinxiu Lu; Fei Ye; Olga Bezouglaia; Elisa Atti; Maria-Grazia Ascenzi; Sotirios Tetradis; Linda Demer; Tara Aghaloo; Yin Tintut
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

5.  Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.

Authors:  Muyesser Sayki Arslan; Esra Tutal; Mustafa Sahin; Melia Karakose; Bekir Ucan; Gulfer Ozturk; Erman Cakal; Zeynep Biyikli Gencturk; Mustafa Ozbek; Tuncay Delibasi
Journal:  Endocrine       Date:  2016-10-15       Impact factor: 3.633

6.  Enhanced mineralization potential of vascular cells from SM22α-Rankl (tg) mice.

Authors:  S Morony; A P Sage; T Corbin; J Lu; Y Tintut; L L Demer
Journal:  Calcif Tissue Int       Date:  2012-10-09       Impact factor: 4.333

7.  An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.

Authors:  Paola Secchiero; Federica Corallini; Assunta Pandolfi; Agostino Consoli; Riccardo Candido; Bruno Fabris; Claudio Celeghini; Silvano Capitani; Giorgio Zauli
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

8.  Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients.

Authors:  Janice J Hwang; Jeffrey Wei; Suhny Abbara; Steven K Grinspoon; Janet Lo
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

9.  Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway.

Authors:  B G Choi; G Vilahur; L Cardoso; J C Fritton; B Ibanez; M U Zafar; D Yadegar; W S Speidl; M B Schaffler; V Fuster; J J Badimon
Journal:  Eur J Clin Invest       Date:  2008-02-12       Impact factor: 4.686

10.  RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.

Authors:  Elizabeth J Samelson; Paul D Miller; Claus Christiansen; Nadia S Daizadeh; Luanda Grazette; Mary S Anthony; Ogo Egbuna; Andrea Wang; Suresh R Siddhanti; Angela M Cheung; Nathalie Franchimont; Douglas P Kiel
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.